List view / Grid view
In this interview, Innate Pharma’s Yannis Morel, Executive Vice President of product portfolio strategy and business development, delves into the unique advantages of using multi-specific antibodies capable of engaging NK cells against tumours for oncology indications, and shares key data from the company’s ongoing and recent clinical trials.
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer...
8 February 2017 | By Brian White and Paul Taylor, Healthcare Analysts, Cantor Fitzgerald Europe
Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures...
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
